LivingGLP1
Descriptive only

Acute pancreatitis

Overweight or obesity without diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network
13
Randomized trials
34
Treatments
5,849
Participants
7
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 13 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
BIMASEMA_SC_1p0-10MG_QWBIMASEMA_SC_1p0-30MG_QWBIMASEMA_SC_2p4-10MG_QWBIMASEMA_SC_2p4-30MG_QWEFPE_SC_4MG_QWEFPE_SC_6MG_Q2WEFPE_SC_6MG_QWEFPE_SC_8MG_Q2WHRS7535_PO_120MG_QDHRS7535_PO_180MG_QDHRS7535_PO_30MG_QDHRS7535_PO_60MG_QDLIRA_SC_3p0MG_QDLOTI_PO_140MG_QDLOTI_PO_160MG_QDLOTI_PO_200MG_QDLOTI_PO_20MG_QDLOTI_PO_260MG_QDLOTI_PO_40MG_QDLOTI_PO_80MG_QDMAZD_SC_16MG_QWMAZD_SC_3MG_QWMAZD_SC_4p5MG_QWMAZD_SC_6MG_QWOTHER_ACTIVE_bimagrumabOTHER_ACTIVE_cagrilintidePLACEBOSEMA_PO_14MG_QDSEMA_SC_1p0MG_QWSEMA_SC_2p4MG_QWVK2735_SC_10MG_QWVK2735_SC_15MG_QWVK2735_SC_2p5MG_QWVK2735_SC_5p0MG_QW
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • NoteOutcome assessment, time point: selected time points span 16.1 to 111 weeks
  • NoteOutcome assessment, analysis set: mixed: randomized 1, safety 12
  • NoteOutcome assessment, definition: mixed: deaths 1, investigator reported pancreatitis 1, not stated 10, serious adverse events 1
  • NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 12, while_on_treatment 1
  • NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 12, treatment_policy 1
  • NoteRisk of bias, blinding: mixed: double_blind 12, open_label 1
  • NoteRisk of bias, funding: mixed: industry 12, mixed 1
  • NoteData handling, input conversions: arms_combined 7
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT0271785816.1safetyserious adverse eventsnot statednot statednot statednot statednot stateddouble_blindindustry2016age 18 to 64, BMI 27 or more, no diabetes, no gallbladder disease
STEP 175safetynot statednot statednot statednot statedwhile_on_treatmenttreatment_policydouble_blindindustry2018adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent
STEP 5111safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2018age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent
NCT0557997728safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
BARIOPTIMISE28randomizednot statednot statednot statednot statednot statednot stateddouble_blindmixed2018adults at least 1 year after RYGB or sleeve gastrectomy with 20 percent or less weight loss and suboptimal GLP-1 response
VENTURE19safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2023age over 18; BMI 30 or more, or 27 or more with comorbidity; BMI 50 or less; no diabetes
NCT0561601348safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2022adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg
NCT0207528126safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes
NCT0490491336safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2021Chinese adults 18 to 75; BMI 28 or more, or 24 or more with comorbidity or hyperphagia; no diabetes, HbA1c below 6.5
NCT0385604726safetyinvestigator reported pancreatitisnot statednot statednot statednot statednot stateddouble_blindindustry2019age 18 or older; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes
NCT0562383927safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes
NCT0625094636safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2024age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent
NCT0155716634safetydeathsnot statednot statednot statednot statednot stateddouble_blindindustry2012age 18 to 64; BMI 30 or more; AHI 15 or more; no diabetes; unable or unwilling to use CPAP

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT02717858A1LIRA_SC_3p0MG_QD16.1arm, events0 / 26R0024932:Results
NCT02717858A2PLACEBO16.1arm, events0 / 26R0024932:Results
STEP 1A1SEMA_SC_2p4MG_QW75arm, events3 / 1,306R0023399:Table 3
STEP 1A2PLACEBO75arm, events0 / 655R0023399:Table 3
STEP 5A1SEMA_SC_2p4MG_QW111arm, events0 / 152R0021896:Table 3
STEP 5A2PLACEBO111arm, events0 / 152R0021896:Table 3
NCT05579977A1+A8PLACEBO28arm, events0 / 139arms_combinedR0004106:Results
NCT05579977A10LOTI_PO_140MG_QD28arm, events0 / 64R0004106:Results
NCT05579977A11+A12LOTI_PO_200MG_QD28arm, events0 / 131arms_combinedR0004106:Results
NCT05579977A13+A6LOTI_PO_260MG_QD28arm, events0 / 138arms_combinedR0004106:Results
NCT05579977A2LOTI_PO_20MG_QD28arm, events0 / 73R0004106:Results
NCT05579977A3LOTI_PO_40MG_QD28arm, events0 / 72R0004106:Results
NCT05579977A4+A9LOTI_PO_80MG_QD28arm, events0 / 139arms_combinedR0004106:Results
NCT05579977A5LOTI_PO_160MG_QD28arm, events0 / 73R0004106:Results
NCT05579977A7SEMA_PO_14MG_QD28arm, events0 / 73R0004106:Results
BARIOPTIMISEA1PLACEBO28arm, events0 / 35R0017334:Results
BARIOPTIMISEA2LIRA_SC_3p0MG_QD28arm, events0 / 35R0017334:Results
VENTUREA1PLACEBO19arm, events0 / 35R0011224:Table 3
VENTUREA2VK2735_SC_2p5MG_QW19arm, events0 / 35R0011224:Table 3
VENTUREA3VK2735_SC_5p0MG_QW19arm, events0 / 35R0011224:Table 3
VENTUREA4VK2735_SC_10MG_QW19arm, events0 / 36R0011224:Table 3
VENTUREA5VK2735_SC_15MG_QW19arm, events0 / 35R0011224:Table 3
NCT05616013A1PLACEBO48arm, events1 / 56R0015266:Table 3
NCT05616013A2+A3OTHER_ACTIVE_bimagrumab48arm, events1 / 113arms_combinedR0015266:Table 3
NCT05616013A4SEMA_SC_1p0MG_QW48arm, events1 / 56R0015266:Table 3
NCT05616013A5SEMA_SC_2p4MG_QW48arm, events0 / 57R0015266:Table 3
NCT05616013A6BIMASEMA_SC_1p0-10MG_QW48arm, events0 / 56R0015266:Table 3
NCT05616013A7BIMASEMA_SC_2p4-10MG_QW48arm, events0 / 56R0015266:Table 3
NCT05616013A8BIMASEMA_SC_1p0-30MG_QW48arm, events0 / 56R0015266:Table 3
NCT05616013A9BIMASEMA_SC_2p4-30MG_QW48arm, events0 / 57R0015266:Table 3
NCT02075281A1PLACEBO26arm, events0 / 60R0011218:Results
NCT02075281A2EFPE_SC_4MG_QW26arm, events0 / 59R0011218:Results
NCT02075281A3EFPE_SC_6MG_QW26arm, events0 / 59R0011218:Results
NCT02075281A4EFPE_SC_6MG_Q2W26arm, events0 / 59R0011218:Results
NCT02075281A5EFPE_SC_8MG_Q2W26arm, events0 / 60R0011218:Results
NCT04904913A1MAZD_SC_3MG_QW36arm, events0 / 62R0016107:Results
NCT04904913A2MAZD_SC_4p5MG_QW36arm, events0 / 63R0016107:Results
NCT04904913A3MAZD_SC_6MG_QW36arm, events0 / 61R0016107:Results
NCT04904913A4PLACEBO36arm, events0 / 62R0016107:Results
NCT03856047A1+A2+A3+A4+A5OTHER_ACTIVE_cagrilintide26arm, events0 / 506arms_combinedR0017871:Results
NCT03856047A6LIRA_SC_3p0MG_QD26arm, events1 / 99R0017871:Results
NCT03856047A7PLACEBO26arm, events0 / 101R0017871:Results
NCT05623839A1PLACEBO27arm, events0 / 8R0013210:Supplement Table S2
NCT05623839A2+A3MAZD_SC_16MG_QW27arm, events0 / 24arms_combinedR0013210:Supplement Table S2
NCT06250946A1PLACEBO36arm, events0 / 46R0001289:Table 6
NCT06250946A2HRS7535_PO_30MG_QD36arm, events0 / 48R0001289:Table 6
NCT06250946A3HRS7535_PO_60MG_QD36arm, events0 / 47R0001289:Table 6
NCT06250946A4HRS7535_PO_120MG_QD36arm, events0 / 46R0001289:Table 6
NCT06250946A5HRS7535_PO_180MG_QD36arm, events0 / 48R0001289:Table 6
NCT01557166A1LIRA_SC_3p0MG_QD34arm, events0 / 180R0026203:Results
NCT01557166A2PLACEBO34arm, events0 / 179R0026203:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab